Page 87 - Read Online

Page 703 Sharma et al. Cancer Drug Resist 2023;6:688-708 https://dx.doi.org/10.20517/cdr.2023.82

DOI PubMed PMC
37. Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell
2011;20:810-7. DOI
38. Yin D, Chen W, O’Kelly J, et al. Connective tissue growth factor associated with oncogenic activities and drug resistance in
glioblastoma multiforme. Int J Cancer 2010;127:2257-67. DOI PubMed
39. Nie E, Jin X, Miao F, et al. TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and
elevated MGMT. Neuro Oncol 2021;23:435-46. DOI PubMed PMC
40. Huang T, Song X, Xu D, et al. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics
2020;10:8721-43. DOI PubMed PMC
41. Mattei V, Santilli F, Martellucci S, et al. The importance of tumor stem cells in glioblastoma resistance to therapy. Int J Mol Sci
2021;22:3863. DOI PubMed PMC
42. Fidoamore A, Cristiano L, Antonosante A, et al. Glioblastoma stem cells microenvironment: the paracrine roles of the niche in drug
and radioresistance. Stem Cells Int 2016;2016:6809105. DOI PubMed PMC
43. Qin Y, Zhang X, Chen Y, Zhang W, Du S, Ren C. Prognostic analysis of a hypoxia-associated lncRNA signature in glioblastoma and
its pan-cancer landscape. J Neurol Surg A Cent Eur Neurosurg 2023. DOI
44. Ren P, Wang JY, Zeng ZR, et al. A novel hypoxia-driven gene signature that can predict the prognosis and drug resistance of
gliomas. Front Genet 2022;13:976356. DOI PubMed PMC
45. Wu Y, Fletcher M, Gu Z, et al. Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour
subtype. Nat Commun 2020;11:6434. DOI PubMed PMC
46. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of
glioblastoma. Cancer Cell 2012;22:425-37. DOI
47. Eyler CE, Matsunaga H, Hovestadt V, Vantine SJ, van Galen P, Bernstein BE. Single-cell lineage analysis reveals genetic and
epigenetic interplay in glioblastoma drug resistance. Genome Biol 2020;21:174. DOI PubMed PMC
48. Zhang S, Guo S, Liang C, Lian M. Long intergenic noncoding RNA 00021 promotes glioblastoma temozolomide resistance by
epigenetically silencing p21 through Notch pathway. IUBMB Life 2020;72:1747-56. DOI PubMed
49. Bezecny P. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience. Med Oncol 2014;31:985. DOI
PubMed
50. Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci
2021;277:119504. DOI PubMed
51. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer
therapy. Cancer Lett 2008;269:7-17. DOI PubMed
52. Zeng J, Li X, Sander M, Zhang H, Yan G, Lin Y. Oncolytic viro-immunotherapy: an emerging option in the treatment of gliomas.
Front Immunol 2021;12:721830. DOI PubMed PMC
53. Gaikwad S, Agrawal MY, Kaushik I, Ramachandran S, Srivastava SK. Immune checkpoint proteins: signaling mechanisms and
molecular interactions in cancer immunotherapy. Semin Cancer Biol 2022;86:137-50. DOI PubMed
54. He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res 2020;30:660-9. DOI PubMed PMC
55. Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol
2015;35 Suppl:S185-98. DOI PubMed
56. Reardon DA, Brandes AA, Omuro A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the
checkmate 143 phase 3 randomized clinical trial. JAMA Oncol 2020;6:1003-10. DOI PubMed PMC
57. Omuro A, Reardon DA, Sampson JH, et al. Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed
glioblastoma: results from exploratory phase I cohorts of checkmate 143. Neurooncol Adv 2022;4:vdac025. DOI PubMed PMC
58. Weller M, Lim M, Idbaih A, et al. CTIM-25. A randomized phase 3 study of nivolumab or placebo combined with radiotherapy plus
temozolomide in patients with newly diagnosed glioblastoma with methylated mgmt promoter: checkmate 548. Neuro-Oncology
2021;23:vi55-6. DOI PMC
59. Sampson JH, Omuro AMP, Preusser M, et al. A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in
combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase
(MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. J Clin Oncol 2016;34:TPS2079. DOI
60. Medikonda R, Dunn G, Rahman M, Fecci P, Lim M. A review of glioblastoma immunotherapy. J Neurooncol 2021;151:41-53. DOI
61. Lin YJ, Mashouf LA, Lim M. CAR T cell therapy in primary brain tumors: current investigations and the future. Front Immunol
2022;13:817296. DOI PubMed PMC
62. Maggs L, Cattaneo G, Dal AE, Moghaddam AS, Ferrone S. CAR T cell-based immunotherapy for the treatment of glioblastoma.
Front Neurosci 2021;15:662064. DOI PubMed PMC
63. Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med
2016;375:2561-9. DOI PubMed PMC
64. Majzner RG, Ramakrishna S, Yeom KW, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature
2022;603:934-41. DOI
65. Siegler EL, Kenderian SS. Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into
mechanisms and novel therapies. Front Immunol 2020;11:1973. DOI PubMed PMC